AIRS experienced a severe operational deterioration with revenue declining 15.8% to $151.8M while operating losses deepened dramatically from -$1.8M to -$11.6M.
The company is facing significant business headwinds as evidenced by closing one center (32 to 31) and removing key competitive advantage language about "100% private pay upfront" and "predictable and recurring revenue." The massive deterioration in operating performance despite SG&A cost cuts suggests fundamental demand or pricing pressures in their body contouring business.
AIRS shows a company in financial distress with revenue falling 15.8% while operating losses exploded over 500% from -$1.8M to -$11.6M, indicating severe operational leverage working against them. Despite management cutting SG&A expenses by 16.9% and slashing capital expenditures by 82.8%, operating cash flow still plummeted 72.7% to just $3.1M. The balance sheet improved modestly with debt reduction and higher equity, but this appears insufficient to offset the dramatic operational deterioration.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Capex reduced 82.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow fell 72.7% — earnings quality concerns; investigate working capital changes and non-cash items.
Net income declined 41.4% — review whether driven by operations, interest costs, or non-recurring items.
Liabilities reduced 23.8% — deleveraging improves balance sheet strength and financial flexibility.
Debt reduced 19.6% — deleveraging strengthens balance sheet and reduces financial risk.
SG&A reduced 16.9% — improved cost efficiency or headcount reduction improving operating margins.
Revenue softened 15.8% — monitor whether this is cyclical or structural.
Total assets contracted 10.8% — asset sales, write-downs, or balance sheet optimization underway.
Equity base grew 10.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →